Lingxin Borui Biotechnology

Beijing Lingxin Borui Biotechnology Co., Ltd., also known as Linxcell, is a high-tech enterprise focused on the research, development, and production of specialized serum-free cell culture media. The company was founded in 2021 and has established a research and development platform that covers raw material screening, formula optimization, and quality control.

Linxcell's core business revolves around providing high-quality, customized culture media for various cell types, including stem cells, immune cells, and organoids. Their products cater to the biopharmaceutical industry, serving clients in cell therapy, antibody and vaccine production, and gene therapy. The company's business model is based on the direct sale of its culture media and providing customized development services to meet specific client needs. A key feature of their offering is the ability to develop serum-free media that is chemically defined, which enhances consistency and safety for cell culture applications, particularly in the context of cell therapy drug development.

The company has achieved significant milestones, including completing an angel round of financing and a Pre-A financing round led by Legend Star, raising tens of millions of yuan to expand its R&D and production capabilities. Linxcell operates a 2000 square meter R&D and production base in Beijing, which includes a GMP-grade production workshop.

Keywords: serum-free media, cell culture, biotechnology, life sciences, cell therapy, biopharmaceutical, organoids, stem cells, custom media development, GMP production